If you haven't started seeing these yet, you will soon. Checkpoint inhibitors are a form of immunotherapy being used for an increasingly broad range of malignancies. They cause a diverse range of adverse events, due to releasing uncontrolled autoimmune hyperactivity. Clinically this can mimic just about any rheumatologic condition. Fortunately these events are quite treatable. However, a high index of suspicion and prompt therapy is important.
This is a new field under explosive development. The chapter will be updated as new studies becomes available (if you find new information that should be included, please alert me in the comments section below). Each sub-section in this chapter is hyperlinked to the American Society of Clinical Oncology 2018 guidelines, currently the single best source for this information.
The IBCC chapter is located here.
- The podcast & comments are below.
Follow us on iTunes
The Podcast Episode
Want to Download the Episode?
Right Click Here and Choose Save-As
- IBCC – Revamped COVID chapter focusing on ICU & stepdown management - January 25, 2021
- IBCC chapter – Disseminated Intravascular Coagulation (DIC) - January 18, 2021
- PulmCrit- RCTs don't justify using convalescent plasma or antibody cocktails - January 14, 2021